RAPT Therapeutics Q2 net loss narrows to $17.6M; pipeline on track for H2 2025 catalysts

RAPT Therapeutics, Inc.

2025-Q2 EPS reported -$1.29

Net loss of $17.6M in Q2 2025, improved from $27.7M in Q2 2024; R&D expenses fell to $12.3M.
Cash and marketable securities totaled $168.9M as of June 30, 2025.
Phase 2b trial of RPT904 in food allergy on track to start H2 2025.
Partner Jemincare to report topline Phase 2 results for RPT904 in CSU and asthma in H2 2025.
Strengthened leadership: Jessica Savage hired; Scott Braunstein and Ashley Dombkowski added to board.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.